Paper30684591
CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M and 5 others. Cancer Lett, 2019. Cited by 218 papers, by iCite.
Cite this record
ConductScience Library. CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Papers, record 30684591. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30684591
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CRISPR-Cas Systems | Major topic |
| Clustered Regularly Interspaced Short Palindromic Repeats | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Gene Editing | |
| Genetic Therapy | |
| Humans |
Source PubMed
Cited by147
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 218 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42909932 | Recent advances in CRISPR technologies for biomedical applications and disease treatment. | Theranostics | 2026 | https://conductscience.org/library/papers/42909932 | PubMed |
| 42864491 | The global patent landscape of CRISPR-Cas applications in medicine. | Nat Biotechnol | 2026 | https://conductscience.org/library/papers/42864491 | PubMed |
| 42852014 | Reassessing Viral Gene Therapy for Glioblastoma: Translational Opportunities and Challenges. | Yale J Biol Med | 2026 | https://conductscience.org/library/papers/42852014 | PubMed |
| 42799027 | Bioengineered T-cell therapies for precision immunotherapy in renal transplantation, autoimmune relapse, and sensitization. | Clin Kidney J | 2025 | https://conductscience.org/library/papers/42799027 | PubMed |
| 42749951 | From scissors to editors: how the evolution of precision is redefining therapeutic genome editing. | Mol Genet Genomics | 2026 | https://conductscience.org/library/papers/42749951 | PubMed |
| 42698535 | Impact of oxidative stress on malignant tumor progression and emerging therapeutic strategies. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42698535 | PubMed |
| 42681653 | KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment. | Biomark Res | 2026 | https://conductscience.org/library/papers/42681653 | PubMed |
| 42642601 | Dissecting Epigenetic Drug Response Mechanisms Using CRISPR Knockout Screens. | Methods Mol Biol | 2026 | https://conductscience.org/library/papers/42642601 | PubMed |
| 42610144 | AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery. | Iran J Basic Med Sci | 2026 | https://conductscience.org/library/papers/42610144 | PubMed |
| 42509343 | TRIM27-Cas9-loaded EVs suppress HCC proliferation and enhance responsiveness to anti-PD-1 therapy by promoting ACSL4-mediated ferroptosis. | Cell Death Differ | 2026 | https://conductscience.org/library/papers/42509343 | PubMed |
| 42467361 | CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation. | MedScience | 2026 | https://conductscience.org/library/papers/42467361 | PubMed |
| 42298891 | Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42298891 | PubMed |
| 42107518 | Modalities of vision restoration in optic neuropathies and retinal disease. | Prog Retin Eye Res | 2026 | https://conductscience.org/library/papers/42107518 | PubMed |
| 42096026 | Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42096026 | PubMed |
| 41999294 | A novel rapid detection approach based on CRISPR-Cas13a for Dermatophagoides pteronyssinus and Dermatophagoides farinae (Acariformes: Pyroglyphidae). | J Insect Sci | 2026 | https://conductscience.org/library/papers/41999294 | PubMed |
| 41984395 | Nanotechnology advances for psoriasis treatment and future prospects. | Discov Nano | 2026 | https://conductscience.org/library/papers/41984395 | PubMed |
| 41930150 | Next-Generation Hydrogel Platforms for Effective Localized Cancer Therapy: Advances in Biologics, Immunotherapeutics, and Gene Delivery. | Oncol Res | 2026 | https://conductscience.org/library/papers/41930150 | PubMed |
| 41893914 | Current and emerging molecular diagnostic approaches in the detection of human parasites. | Parasitol Res | 2026 | https://conductscience.org/library/papers/41893914 | PubMed |
| 41876645 | Synergistic integration of CRISPR/Cas and nanozymes in next-generation biosensors for ultrasensitive bacterial detection. | Mikrochim Acta | 2026 | https://conductscience.org/library/papers/41876645 | PubMed |
| 41755409 | CRISPR-Cas9 Gene Editing: Promising Therapeutics for HPV-driven Cervical Cancer. | Curr Drug Targets | 2026 | https://conductscience.org/library/papers/41755409 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30684591
GET https://conductscience.org/api/papers/v1/30684591/cited_by?page=2